BGMS · Bio Green Med Solution, Inc. · Exempt Offerings
Substantial doubt about the company's ability to continue as a going concern.
“Our history of losses, our negative cash flows from operations, our liquidity resources currently on hand, and our dependence on the ability to obtain additional financing to fund our operations after the current resources are exhausted, about which there can be no certainty, have resulted in our assessment that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
4 customers — 55% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 36% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 7% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 6% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 6% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2025-03-25 | New | Biotechnology | $1,000,000 | $1,000,000 | 06b |
| 2025-02-14 | New | Biotechnology | $25,000,000 | $0 | 06b |
| 2025-02-14 | New | Biotechnology | $0 | $0 | 06b |
| 2024-11-26 | New | Biotechnology | $2,062,112 | $2,062,112 | 06b |
| 2024-05-17 | New | Biotechnology | $8,000,000 | $8,000,000 | 06b |
| 2021-01-04 | New | Biotechnology | $7,000,000 | $7,000,000 | 06b |